drugset / Trial / NCT05945888

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

NCT05945888

Phase 1 Completed 68 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The single rising dose (SRD) part of the trial investigates safety, tolerability, and pharmacokinetics of BI 3000202. The food effect (FE) part is conducted to assess the effect of food on the relative bioavailability of the BI 3000202 formulation.

Timeline

Start
2023-07-25
Primary completion
2023-11-13
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3000202 Unknown Oral

Indications

No indication recorded.